Literature DB >> 8655369

Potential doubling time and clinical outcome in head and neck squamous cell carcinoma treated with 70 GY in 7 weeks.

J Bourhis1, R Dendale, C Hill, J Bosq, F Janot, P Attal, A Fortin, P Marandas, G Schwaab, P Wibault, E P Malaise, S Bobin, B Luboinski, F Eschwege, G Wilson.   

Abstract

PURPOSE: To study the predictive value of pretreatment potential doubling time and labeling index, as measured by flow cytometry in patients with head and neck squamous cell carcinoma treated with conventional radiotherapy. METHODS AND MATERIALS: 70 patients with a squamous cell carcinoma of the oropharynx and 4 patients with another involved head and neck site were entered in this prospective study. The duration of the S phase (TS), the labeling index (LI), and the potential doubling time (Tpot) were obtained by flow cytometry measurements of a tumor biopsy obtained after i.v. injection of 200 mg bromodeoxyuridine to the patient. The treatment consisted of 70 Gy in 7 weeks, 2 Gy per fraction and five fractions per week.
RESULTS: The mean and median LI were 7.7% (standard deviation, SD: 5.0) and 6.3%, respectively. The mean and median TS were 9.3 h (SD: 3.6) and 8.3 h, respectively. The mean and median Tpot were 5.6 days (SD: 5.4) and 4.6 days, respectively. No significant relationship was found between the Tpot or LI and the tumor stage (T), nodal status (N), histological grade, and the site of the primary within the oropharynx. The only parameter significantly associated with an increased risk of local relapse was the tumor stage (p < 0.001). The mean Tpot for the group of tumors that relapsed locally was 5.3 days (SD: 3.3), compared to 6.1 days (SD: 4.08) for those who did not relapse locally (NS). Two parameters were significantly associated with a decrease in disease-free (DFS) and overall survival, namely the tumor stage (p < 0.005, and p < 0.001, respectively, for DFS and overall survival) and nodal involvement (p = 0.02 and (p < 0.005, respectively, for DFS and overall survival). The TS, LI, DNA index, and Tpot were not significantly associated with local relapse, DFS, and survival, either in the univariate or in the multivariate analysis.
CONCLUSIONS: The method used to evaluate tumor cell kinetics did not provide clinically relevant kinetic parameters for this type of cancer. The classic prognostic factors (tumor stage and nodal status) were strongly associated with clinical outcome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8655369     DOI: 10.1016/s0360-3016(96)80008-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Radiotherapy and risks of tumor regrowth or inducing second cancer.

Authors:  Emad Y Moawad
Journal:  Cancer Nanotechnol       Date:  2011-08-18

2.  Importance of tumor volume in supraglottic and glottic laryngeal carcinoma.

Authors:  L W van Bockel; E M Monninkhof; F A Pameijer; C H J Terhaard
Journal:  Strahlenther Onkol       Date:  2013-11-08       Impact factor: 3.621

3.  A molecular assay of tumor radiosensitivity: a roadmap towards biology-based personalized radiation therapy.

Authors:  Javier F Torres-Roca
Journal:  Per Med       Date:  2012-07       Impact factor: 2.512

4.  Prognostic values of proliferating cell nuclear antigen (PCNA) and Ki-67 for radiotherapy of oesophageal squamous cell carcinomas.

Authors:  Y Okuno; Y Nishimura; I Kashu; K Ono; M Hiraoka
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

5.  Applicability of the linear-quadratic model to single and fractionated radiotherapy schedules: an experimental study.

Authors:  Akifumi Miyakawa; Yuta Shibamoto; Shinya Otsuka; Hiromitsu Iwata
Journal:  J Radiat Res       Date:  2013-12-17       Impact factor: 2.724

6.  Impact of delays in radiotherapy of head and neck cancer on outcome.

Authors:  Barbara Žumer; Maja Pohar Perme; Simona Jereb; Primož Strojan
Journal:  Radiat Oncol       Date:  2020-08-20       Impact factor: 3.481

7.  Unforeseen Computed Tomography Resimulation for Initial Radiation Planning: Associated Factors and Clinical Impact.

Authors:  April Metzger; Paul Renz; Shaakir Hasan; Stephen Karlovits; Jason Sohn; Steven Gresswell
Journal:  Adv Radiat Oncol       Date:  2019-06-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.